ZymoGenetics establishes global collaboration with Bayer for development and commercialization of recombinant human thrombin.
Publication Date: 01-JUN-07
Publication Title: BIOTECH Patent News
Format: Online
Company: ZymoGenetics Inc.

Read this article now
Try Goliath Business News - FREE!
You can view this article PLUS...

  • Over 5 million business articles
  • Hundreds of the most trusted magazines, newswires, and journals (see list)
  • Premium business information that is timely and relevant
  • Unlimited Access

Now for a Limited Time, try Goliath Business News
Free for 7 Days!

Tell Me More   Terms and Conditions

Purchase this article for $4.95

Description

ZymoGenetics, Inc.(Seattle, WA) entered into multi-year, domestic and global license and collaboration agreements with Bayer HealthCare (Leverkusen, Germany) to maximize the potential of ZymoGenetics' most advanced product candidate, recombinant human thrombin (rThrombin). ZymoGenetics retains United States product rights. As part of a co-promotion agreement, Bayer HealthCare will contribute its sales and marketing expertise for the first three years following product launch, with the expectation that the two firms will maximize penetration of the product into the United States market.

Bayer HealthCare will commercialize rThrombin in all countries outside the United States, leveraging the company's strong commercial presence in these markets. Bayer HealthCare will be responsible for any required clinical trials and securing regulatory approvals and commercializing the product...



More articles from BIOTECH Patent News
Genentech obtains United States patent., June 01, 2007
Roche obtains United States patent., June 01, 2007
Pharma Pacific obtains United States patent., June 01, 2007
Bayer obtains United States patent., June 01, 2007
Cayla obtains United States patent., June 01, 2007

Looking for additional articles?
Click here to search our database of over 3 million articles.